Research programme: menstrual blood stem cell therapies - Cryo-Cell International

Drug Profile

Research programme: menstrual blood stem cell therapies - Cryo-Cell International

Alternative Names: Human menstrual blood-derived mesenchymal stem cells - Cryo-Cell

Latest Information Update: 20 May 2015

Price : $50

At a glance

  • Originator Cryo-Cell International
  • Developer Cryo-Cell International; Cryopraxis; Monash University
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Endometriosis; Multiple sclerosis; Urinary incontinence

Most Recent Events

  • 24 Jul 2013 No development reported - Preclinical for Multiple sclerosis in Australia (Parenteral)
  • 24 Jul 2013 No development reported - Preclinical for Urinary incontinence in Brazil (Parenteral)
  • 24 Jul 2013 No development reported - Preclinical for Endometriosis in Brazil (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top